Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
SPN Monoclonal Antibody (OTI2D4), TrueMAB™, OriGene

Mouse Monoclonal Antibody
Supplier: OriGene TA800786

Description
CD43 (leukosialin, sialophorin) is a transmembrane mucin-like protein with high negative charge, expressed on the surface of most hematopoietic cells. CD43 contributes to a repulsive barrier that interferes with cellular adhesion, however, in certain cases also promotes leukocyte aggregation. By interaction with actin-binding proteins ezrin and moesin CD43 plays a regulatory role in remodeling T-cell morphology and regulates cell-cell interactions during lymphocyte traffic. CD43 signaling both enhances LFA-1 adhesiveness and counteracts LFA-1 induction via other receptors. Expression of CD43 causes induction of functionally active tumor suppressor p53 protein, but in case of p53 and ARF deficiency CD43 promotes tumor proliferation and viability. CD43 appears to be an important modulator of leukocyte functions. Diseases associated with CD43 dysfunction include Wiscott-Aldrich Syndrome and Adenoid Basal Cell Carcinoma.Specifications
SPN | |
Monoclonal | |
1 mg/mL | |
PBS with 1% BSA, 50% glycerol and 0.02% sodium azide | |
P16150 | |
SPN | |
Full length human recombit protein of human SPN produced in HEK293T cell. | |
100 μL | |
Primary | |
Human | |
Antibody | |
IgG1 |
Western Blot | |
OTI2D4 | |
Unconjugated | |
SPN | |
CD43, GALGP, GPL115, LSN | |
Mouse | |
Affinity Chromatography | |
RUO | |
6693 | |
-20° C, Avoid Freeze/Thaw Cycles | |
Liquid |
Product Content Correction
The Fisher Scientific Encompass Program offers items which are not part of our distribution portfolio. These products typically do not have pictures or detailed descriptions. However, we are committed to improving your shopping experience. Please use the form below to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction